# Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

> **NCT02497976** · PHASE3 · COMPLETED · sponsor: **ICStudy, LLC** · enrollment: 42 (actual)

## Conditions studied

- Cystitis, Interstitial

## Interventions

- **BIOLOGICAL:** Certolizumab pegol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02497976
- **Lead sponsor:** ICStudy, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-15
- **Primary completion:** 2017-04-16
- **Final completion:** 2017-07-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2018-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02497976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02497976, "Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02497976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*